BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oster P, Vaillant L, Riva E, McMillan B, Begka C, Truntzer C, Richard C, Leblond MM, Messaoudene M, Machremi E, Limagne E, Ghiringhelli F, Routy B, Verdeil G, Velin D. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut 2022;71:457-66. [PMID: 34253574 DOI: 10.1136/gutjnl-2020-323392] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Huang X, Tong D, Jiang C, Zhu X, Wei Z, Gong T, Jin C. Relationships among microbiota, gastric cancer, and immunotherapy. Front Microbiol 2022;13:987763. [DOI: 10.3389/fmicb.2022.987763] [Reference Citation Analysis]
2 Wu B, Sun C, Sun X, Li X. Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients. Medicine (Baltimore) 2022;101:e30532. [PMID: 36086697 DOI: 10.1097/MD.0000000000030532] [Reference Citation Analysis]
3 Agnarelli A, Vella V, Samuels M, Papanastasopoulos P, Giamas G. Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications. Cancers 2022;14:4378. [DOI: 10.3390/cancers14184378] [Reference Citation Analysis]
4 Cai H, Li M, Deng R, Wang M, Shi Y. Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy. Biomark Res 2022;10:67. [PMID: 36042469 DOI: 10.1186/s40364-022-00413-0] [Reference Citation Analysis]
5 Shi Y, Zheng H, Guo Z, Deng R, Yu W, Song Y, Ding S. Effect of Helicobacter pylori on immunotherapy is gaining more attention. Helicobacter 2022;:e12925. [PMID: 36036113 DOI: 10.1111/hel.12925] [Reference Citation Analysis]
6 Shao B, Chai N, Yao Y, Li J, Law HKW, Linghu E. Autophagy in gastrointestinal cancers. Front Oncol 2022;12:975758. [DOI: 10.3389/fonc.2022.975758] [Reference Citation Analysis]
7 Che H, Xiong Q, Ma J, Chen S, Wu H, Xu H, Hou B. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-10004-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Deng R, Zheng H, Cai H, Li M, Shi Y, Ding S. Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. Front Immunol 2022;13:923477. [DOI: 10.3389/fimmu.2022.923477] [Reference Citation Analysis]
9 Liang H, Jo J, Zhang Z, Macgibeny MA, Han J, Proctor DM, Taylor ME, Che Y, Juneau P, Apolo AB, Mcculloch JA, Davar D, Zarour HM, Dzutsev AK, Brownell I, Trinchieri G, Gulley JL, Kong HH. Predicting cancer immunotherapy response from gut microbiomes using machine learning models. Oncotarget 2022;13:876-89. [DOI: 10.18632/oncotarget.28252] [Reference Citation Analysis]
10 Yang J, Yang H, Li Y. The triple interactions between gut microbiota, mycobiota and host immunity. Crit Rev Food Sci Nutr 2022;:1-21. [PMID: 35776086 DOI: 10.1080/10408398.2022.2094888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhou M, Yang W, Xuan Y, Zou W, Wang Y, Zhang Z, Zhang J, Mo M, Zhou C, Liu Y, Zhang W, Zhang Z, He Y, Weng W, Tan C, Wang L, Huang D, Sheng W, Li H, Zhu H, Wang Y, Shen L, Zhang H, Wan J, Li G, Huang H, Wang Y, Zhang Z, Liu X, Xia F. A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09786-9] [Reference Citation Analysis]
12 . H. pylori mindert Effektivität von Krebsimmuntherapien. Z Gastroenterol 2022;60:901-2. [DOI: 10.1055/a-1795-5459] [Reference Citation Analysis]
13 Neuper T, Frauenlob T, Posselt G, Horejs-hoeck J. Beyond the gastric epithelium — the paradox of Helicobacter pylori-induced immune responses. Current Opinion in Immunology 2022;76:102208. [DOI: 10.1016/j.coi.2022.102208] [Reference Citation Analysis]
14 Oster P, Vaillant L, Mcmillan B, Velin D. The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection. Front Immunol 2022;13:899161. [DOI: 10.3389/fimmu.2022.899161] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Birla P, Shaikh FY. De- "bug"-ing the microbiome in lung cancer. Cancer Metastasis Rev 2022. [PMID: 35588337 DOI: 10.1007/s10555-022-10036-4] [Reference Citation Analysis]
16 Chen X, Zou Y, Zhang S, Fang P, Li S, Li P, Sun Y, Yuan G, Hu H. Multi-functional vesicles improve Helicobacter pylori eradication by a comprehensive strategy based on complex pathological microenvironment. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.014] [Reference Citation Analysis]
17 Ivey A, Pratt H, Boone BA. Molecular pathogenesis and emerging targets of gastric adenocarcinoma. J Surg Oncol 2022;125:1079-95. [PMID: 35481910 DOI: 10.1002/jso.26874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Park CH, Hong C, Lee A, Sung J, Hwang TH. Multi-omics reveals microbiome, host gene expression, and immune landscape in gastric carcinogenesis. iScience 2022;25:103956. [DOI: 10.1016/j.isci.2022.103956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Sitkin S, Lazebnik L, Avalueva E, Kononova S, Vakhitov T. Gastrointestinal microbiome and Helicobacter pylori: Eradicate, leave it as it is, or take a personalized benefit–risk approach? World J Gastroenterol 2022; 28(7): 766-774 [DOI: 10.3748/wjg.v28.i7.766] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Shi Y, Zheng H, Wang M, Ding S. Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention. Helicobacter 2022;:e12878. [PMID: 35112435 DOI: 10.1111/hel.12878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Newsome RC, Yang Y, Jobin C. The microbiome, gastrointestinal cancer, and immunotherapy. J Gastroenterol Hepatol 2021. [PMID: 34820895 DOI: 10.1111/jgh.15742] [Reference Citation Analysis]
22 Chua TH, Punjabi LS, Khor LY. Tissue Pathogens and Cancers: A Review of Commonly Seen Manifestations in Histo- and Cytopathology. Pathogens 2021;10:1410. [PMID: 34832566 DOI: 10.3390/pathogens10111410] [Reference Citation Analysis]